ArticleJournal of diabetes2023
Evaluating the role of time in range as a glycemic target during short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes.
Article in Journal of diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Effects of Short-Term Intensive Insulin Therapy Combined With Oral Hypoglycemic Agents for Inducing Remission in Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Clinical Trial.Journal of diabetes · 2026Trial
- Evaluating Intensive Insulin Therapy With Empagliflozin in Type 2 Diabetes: A Randomised Study.Endocrinology, diabetes & metabolism · 2025Trial
- Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment.Journal of diabetes investigation · 2025Trial
- Maintained diabetes remission among normal BMI individuals achieved without ongoing intervention: a three-year follow-up study of intermittent calorie restriction.Frontiers in endocrinology · 2025Trial
- Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.BMJ (Clinical research ed.) · 2024Trial
- Construction and Implications of Nomogram for Predicting Sustained Glycemic Remission After Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes.Journal of diabetes · 2025Article
- Time in target range for systolic blood pressure and glucose with cardiovascular disease and all-cause mortality risks.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Risk factor screening and predictive modeling of time-in-range in patients with T2DM undergoing SIIT therapy.Frontiers in endocrinology · 2025Article
- Simplicity: The Ultimate Sophistication in Managing Type 2 Diabetes With Severe Hyperglycemia.Journal of diabetes · 2024Article
- Decreased circulating dipeptidyl peptidase-4 activity after short-term intensive insulin therapy predicts clinical outcomes in patients with newly diagnosed type 2 diabetes.Frontiers in endocrinology · 2024Article
- Comprehensive retinal vascular measurements: time in range is associated with peripheral retinal venular calibers in type 2 diabetes in China.Acta diabetologica · 2023Article
- Evaluating the role of time in range as a glycemic target during short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes.Journal of diabetes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundTight glycemic control during short-term intensive insulin therapy (SIIT) is critical for inducing diabetes remission in patients with newly diagnosed type 2 diabetes (T2D). This work aimed to investigate the role of time in range (TIR) during SIIT as a novel glycemic target by predicting clinical outcomes.
methodsSIIT was given to 116 patients with newly diagnosed T2D, with daily eight-point capillary glucose monitored. Glycemic targets (fasting/premeal glucose, 3.9-6.0 mmol/L; 2 h postprandial blood glucose, 3.9-7.8 mmol/L) were achieved and maintained for 2 weeks. TIR
resultsTIR
conclusionsThese findings advocate TIR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.